Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, ...

Metabolic bariatric surgery (MBS) is associated with improved outcomes in patients with psoriasis, according to a review ...

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly ...

In 2025, over 200,000 Americans were diagnosed with skin cancer. Thankfully, five months ago, U.S. Dermatology Partners ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...